Contineum Therapeutics CTNM Cash Flow Statement (2023-2026)

NASDAQ CTNM
$10.77 +0.21 (+1.99%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Contineum Therapeutics Quarterly Cash Flow Statement

Periods 15 quarters
Latest Sep 2026

Contineum Therapeutics reported cash from operations of -$11.06M and free cash flow of -$11.06M for the quarter ended Sep 2026, up 9.3% year over year. This cash flow statement covers 15 quarters of results from Mar 2023 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income -4.82M41.56M-6.25M-7.77M-8.42M-9.01M-10.27M-14.57M-15.99M-16.04M-12.79M-15.18M-14.46M-15.15M-18.70M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges 0.03M-0.22M0.00M
Depreciation & Amortization (CF)Dep. & Amort. 0.07M0.04M0.04M0.04M0.06M0.06M0.06M0.12M0.08M0.08M0.08M0.09M0.08M0.13M0.08M
Share-based CompensationStock Comp. 0.49M0.49M0.48M0.76M0.77M1.49M2.29M2.25M2.57M0.27M2.57M2.48M3.82M3.84M4.86M
Gains from Sales and DivestituresGains Divest 0.02M-0.07M0.00M
Gains from Investment SecuritiesGains Investment -0.02M0.00M0.00M0.01M0.00M0.00M0.01M
Other non-cash itemsOther Non-Cash -0.02M0.00M-0.94M-0.66M-0.01M-0.91M-0.05M0.28M0.23M-0.33M1.07M
Change in Working Capital
Change in Account PayablesChange Payables 0.28M-0.31M0.66M-0.63M-0.07M0.17M0.66M0.38M1.83M-1.64M-1.22M0.16M0.49M-0.99M0.14M
Change in Accrued ExpensesChange Accrued Exp. -0.98M2.15M2.02M-1.61M-0.38M-1.46M1.21M2.94M-2.86M-0.10M0.35M2.10M-3.53M0.77M1.03M
Change in Other Operating AssetsOther Assets Change 0.06M-0.08M1.30M-0.01M-0.71M-1.07M-0.44M0.39M-0.20M-0.06M1.17M2.50M1.62M-0.61M-0.77M
Change in Other Operating LiabilitiesOther Liabilities Change -0.26M-0.25M-0.26M-0.57M0.01M0.01M0.01M0.03M-0.26M-0.25M-0.26M-0.50M-1.30M-0.38M-0.31M
Other Working Capital ChangesOther WC Changes -0.32M-0.18M-1.56M-0.56M0.73M1.08M0.45M-0.37M-0.05M-0.19M-1.42M-2.99M-2.91M0.23M0.46M
Cash from OperationsCash from Ops. -5.24M40.67M-5.38M-10.70M-7.98M-8.50M-6.17M-10.20M-14.41M-15.66M-12.20M-13.04M-16.27M-11.50M-11.06M
Investing Activities
Capital ExpendituresCapex 0.05M0.03M0.02M0.31M0.15M0.12M0.08M0.17M0.05M0.04M0.10M0.04M0.31M0.01M
Change in Property, Plant and EquipmentChange in PP&E -0.05M-0.03M-0.02M-0.31M-0.15M-0.12M-0.08M-0.17M-0.05M-0.04M-0.10M-0.04M-0.31M-0.01M
Purchase of InvestmentsInvestments Purchased 9.22M58.58M52.08M22.00M30.64M69.01M72.41M54.35M33.69M25.44M18.64M84.73M97.12M45.79M16.04M
Sale and Maturity of InvestmentsInvestments Sold 18.62M14.15M12.60M31.34M39.52M30.23M42.28M45.13M48.65M39.37M33.68M37.32M58.12M50.65M67.00M
Cash from Investing ActivitiesCash from Investing 9.36M-44.46M-39.50M9.03M8.73M-38.90M-30.18M-9.39M14.92M13.88M14.94M-47.45M-39.31M4.85M50.95M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt RepaymentsLT Debt Repayment 0.63M3.13M
Net Long-Term Debt Issued (Repaid)Net LT Debt -0.63M-3.13M
Net Debt Issuances and RepaymentsNet Debt Issuance -0.63M-3.13M
Change in Capital Stock
Common Stock IssuedStock Issued 0.01M0.02M0.08M0.05M0.12M108.22M-108.20M0.64M0.02M0.27M19.19M-18.79M0.20M1.25M20.53M
Net Shares Issued and RepurchasedNet Shares Issued 0.01M0.02M0.08M0.05M0.12M108.22M-108.20M0.64M0.02M0.27M19.19M-18.79M0.20M1.25M20.53M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued 10.24M
Net Equity Issued and RepurchasedNet Equity Issued 0.01M0.02M10.33M0.05M0.12M108.22M-108.20M0.64M0.02M0.27M19.19M-18.79M0.20M1.25M20.53M
Other financing activities (as filed) -0.14M0.14M-0.18M-0.08M-0.07M-0.05M0.06M
Cash from Financing ActivitiesCash from Financing -0.62M46.79M10.33M-0.32M-0.02M108.36M0.01M0.64M0.02M0.09M19.11M93.47M0.13M1.20M20.59M
Additional items
Change in Cash 3.49M43.01M-34.55M-2.00M0.74M60.97M-36.34M-18.95M0.53M-1.69M21.85M32.97M-55.45M-5.45M60.49M
Ending Cash Balance 9.06M52.07M17.52M15.53M16.26M77.23M40.89M21.94M22.47M20.78M42.63M75.60M20.16M14.71M75.20M
Free Cash FlowFCF -5.30M40.64M-5.40M-11.01M-8.12M-8.62M-6.25M-10.37M-14.46M-15.71M-12.30M-13.08M-16.58M-11.51M-11.06M
Net Cash FlowNCF 3.49M43.01M-34.55M-2.00M0.74M60.97M-36.34M-18.95M0.53M-1.69M21.85M32.97M-55.45M-5.45M60.49M

Contineum Therapeutics Cash Flow Statement API

Pull Contineum Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=CTNM&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY